Evaluating Three Methods for Helping Syringe Exchangers Begin Methadone Maintenance
This research is being done to evaluate the effectiveness of three different treatment strategies for helping subjects begin and adjust to methadone maintenance treatment at Addiction Treatment Services (ATS). Subjects will be randomly assigned to one of three treatment conditions: 1) Voucher-Based Stepped Care (VBSC) induction, 2) Low-threshold Stepped Care (LTSC) induction, or 3) Routine Stepped Care (RSC) induction. It is hypothesized that subjects in both the VBSC and LTSC condition will remain in treatment longer than subjects in the RSC condition. In addition, it is hypothesized that VBSC and LTSC subjects will have less drug-positive urine samples and will report less infectious disease risk behaviors than RSC subjects.
Substance Abuse Disorder
Behavioral: Low intensity care
Behavioral: Voucher reinforcement
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Health Services Research
|Official Title:||Evaluating Three Methods for Helping Syringe Exchangers Begin Methadone Maintenance|
- Treatment retention and time to dropout [ Time Frame: Weekly for 26 weeks ] [ Designated as safety issue: No ]The length of time subjects remain in treatment is tracked throughout the study. Retention will be assessed as: 1) percent of subjects remaining in treatment at 3 and 6-months, and 2) time to dropout.
- Substance use [ Time Frame: Weekly for 26 weeks ] [ Designated as safety issue: No ]Subjects are required to leave weekly urine specimens (for 12-weeks) which are tested for drugs of abuse. Percent positive for opiates, cocaine, benzodiazepines, and cannabis will be evaluated weekly. Self-report use will be assessed for subjects in and out of treatment.
- Infectious disease risk behaviors [ Time Frame: Monthly for 6 months ] [ Designated as safety issue: No ]Risk behavior will be assessed via the the Risk Assessment Battery (RAB) and Addiction Severity Index at baseline and monthly intervals throughout the study for subjects in and out of treatment.
- Other problem severity [ Time Frame: Monthly for 6 months ] [ Designated as safety issue: No ]Addiction Severity Index (ASI) composite scores will be assessed at baseline and at monthly intervals.
- Counseling engagement [ Time Frame: Weekly for 26 weeks ] [ Designated as safety issue: No ]Total number of individual and group counseling sessions attended, as well as adherence to scheduled sessions (i.e. attended/scheduled), will be monitored.
- Methadone dose [ Time Frame: Weekly for 26 weeks ] [ Designated as safety issue: No ]Mean methadone dose, days receiving methadone, and dose adequacy will be evaluated.
- Treatment readiness [ Time Frame: Monthly for 6 months ] [ Designated as safety issue: No ]Treatment readiness will be assessed via the TCU Treatment Motivation Scales (TMS) at baseline and monthly intervals.
- Treatment satisfaction [ Time Frame: Monthly for 6 months ] [ Designated as safety issue: No ]The Client Satisfaction Questionnaire (CSQ) will assess treatment satisfaction at baseline and monthly intervals.
- Use of syringe exchange and other community-based services [ Time Frame: Monthly for 6 months ] [ Designated as safety issue: No ]Days of syringe exchange program (SEP) use, number of syringes exchanged, and use of other community-based medical and psychosocial resources (e.g. emergency room, psychiatric and other treatment facilities, shelters, hospitalization) will be assessed for participants in and out of treatment at baseline and monthly intervals.
|Study Start Date:||July 2010|
|Estimated Primary Completion Date:||January 2016 (Final data collection date for primary outcome measure)|
Experimental: Low Threshold Stepped Care (LTSC)
Subjects in this condition will receive low intensity care during the first 3-months (13 weeks) of study participation, and usual counseling care during the final 3-months (13 weeks) of participation.
Behavioral: Low intensity care
During the first 3-months (13 weeks), subjects will be scheduled to attend one individual counseling session per month. Subjects will not be required to attend any group counseling sessions during this time. After the first 3-months of care, subjects will start usual counseling care, at which time they will be required to attend one individual counseling session per week, and may be required to attend additional individual and group counseling sessions each week for missed sessions or continued use of drugs or alcohol.
Experimental: Voucher-Based Stepped Care (VBSC)
Subjects in this condition will receive usual counseling care during the entire 6 months of study participation. They will receive voucher reinforcement, and will have the opportunity to earn voucher incentives during the first 3-months of care (13 weeks).
Behavioral: Voucher reinforcement
Subjects will receive usual counseling care during the 26 weeks of study participation.They will be required to attend one individual counseling session per week, and will be required to attend additional individual and group sessions each week for missed session or continued use of drugs or alcohol.In addition, subjects in this condition will have the opportunity to earn voucher incentives each week during the first 13 weeks of care.These incentives can be earned by taking daily methadone doses and attending all scheduled counseling sessions (individual and group).The first voucher is worth $12.00, and each voucher after that is worth an additional $13.50. Bonuses of $30.00 will be awarded for each 3 consecutive weeks of compliance.The total amount possible to earn in the study is $1329.00. Each week that the subject is not compliant,they will not earn a voucher and the value of the next voucher will be reset to $12.00.The vouchers can be used for goods and services in the community.
No Intervention: Routine Stepped-Care (RSC)
Subjects in this condition will receive usual counseling care during the entire 6-month study (26 weeks).
This study will evaluate two alternative methods of inducting syringe exchange referrals into routine methadone treatment. The sample (N=390) will be opioid-dependent injection drug users referred by the Baltimore Needle Exchange Program (BNEP) for routine outpatient methadone treatment using a stepped care model. Subjects will be randomly assigned to one of three 3-month treatment induction conditions: 1) Low Threshold Stepped Care induction (LTSC), 2) Voucher-Based Stepped Care induction (VBSC), or 3) Routine Stepped-Care induction (RSC). The LTSC condition will noticeably reduce treatment demands on new admissions during the 90-day induction period and is conceptually related to an interim maintenance schedule. It is expected to increase patient recognition of the reinforcing effects and benefits of methadone, improve the transition to more comprehensive schedules of care, and increase early retention. The VBSC condition adds an attendance reinforcement intervention to the routine stepped care induction schedule over the first 90-days of treatment. It is expected to improve early treatment engagement and retention. Subjects in each of these conditions will transition to routine stepped-care (no voucher-based reinforcement) following the 90-day induction period. The RSC condition will serve as a comparison group and represents routine care in the program where the study will be conducted. All subjects will be followed for 6-months. Retention, drug use (via urinalysis and self-report), and other infectious disease risk behaviors (e.g., syringe sharing; number of injections) are the primary outcome measures. The proposed design will also test mediational models to evaluate changes in objective indices of engagement (methadone and counseling adherence) and psychological constructs (treatment readiness and satisfaction) as predictors of outcome. Regression models will be used to evaluate the amount of reduction of drug use necessary to effect varying amounts of change in HIV risk behavior. Finally, data will be collected and compared on the treatment costs of each induction strategy.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01142986
|Contact: Kori Kindbom, MA||(410) email@example.com|
|United States, Maryland|
|Addiction Treatment Services||Recruiting|
|Baltimore, Maryland, United States, 21224|
|Contact: Kori Kindbom, MA 410-550-0984|
|Principal Investigator: Michael Kidorf, Ph.D.|
|Principal Investigator:||Michael Kidorf, Ph.D.||Johns Hopkins University|